Insight Molecular Diagnostics (IMDX) EBIAT (2020 - 2025)
Insight Molecular Diagnostics' EBIAT history spans 6 years, with the latest figure at -$10.9 million for Q3 2025.
- For Q3 2025, EBIAT rose 19.56% year-over-year to -$10.9 million; the TTM value through Sep 2025 reached -$60.8 million, down 31.93%, while the annual FY2024 figure was -$60.7 million, 118.36% down from the prior year.
- EBIAT for Q3 2025 was -$10.9 million at Insight Molecular Diagnostics, down from -$9.7 million in the prior quarter.
- Across five years, EBIAT topped out at $6.0 million in Q1 2023 and bottomed at -$45.0 million in Q4 2022.
- The 5-year median for EBIAT is -$9.3 million (2022), against an average of -$12.9 million.
- The largest annual shift saw EBIAT crashed 468.79% in 2021 before it surged 274.6% in 2023.
- A 5-year view of EBIAT shows it stood at -$35.9 million in 2021, then decreased by 25.34% to -$45.0 million in 2022, then soared by 57.94% to -$18.9 million in 2023, then plummeted by 77.14% to -$33.5 million in 2024, then surged by 67.61% to -$10.9 million in 2025.
- Per Business Quant, the three most recent readings for IMDX's EBIAT are -$10.9 million (Q3 2025), -$9.7 million (Q2 2025), and -$6.7 million (Q1 2025).